Drug Profile
TAK 101
Alternative Names: CNP-101; Cour-NP-GLI; TAK-101; TIMP-GLIA; TIMP/GliadinLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Cour Pharmaceutical Development
- Developer Cour Pharmaceutical Development; Takeda
- Class Digestion aids; Polymers; Proteins
- Mechanism of Action Immunomodulators; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Coeliac disease
Most Recent Events
- 23 Jun 2022 Phase-II clinical trials in Coeliac disease (Prevention, In adults, In the elderly) in USA (IV) (NCT04530123)
- 11 May 2021 Takeda expects approval for Coeliac disease in FY 2025 (Takeda pipeline, May 2021)
- 09 Mar 2021 Phase-II development is ongoing in in Coeliac disease in USA (IV) (NCT03738475)